|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1455 PENNSYLVANIA AVENUE NW |
Address2 | SUITE 500 |
| City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Bridgewater |
State | NJ |
Zip Code | 08807 |
Country | USA |
|
5. Senate ID# 56838-12
|
||||||||
|
6. House ID# 351860000
|
||||||||
| TYPE OF REPORT | 8. Year | 2017 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Adam Gluck |
Date | 4/20/2017 5:32:44 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, Section 202 Tropical disease product application; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 469 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to insulin pricing; general issues related to drug pricing and general issues related to Vaccine safety.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
MaryAnne |
Dunlap |
|
|
|
Amy |
Redl |
|
|
|
Francis |
Rienzo |
|
|
|
Jacob |
Hartsfield |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
General issues related to border adjustability tax; issues related to interest deductibility; issues related to H.R. 394 Restoring Access to Medication Act of 2017' issues related to S. 85 Restoring Access to Medication Act of 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
MaryAnne |
Dunlap |
|
|
|
Amy |
Redl |
|
|
|
Francis |
Rienzo |
|
|
|
Jacob |
Hartsfield |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to the repeal of Non-Interference in Part D; general issues related to S.260 "Protecting Seniors' Access to Medicare Act of 2017".
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
MaryAnne |
Dunlap |
|
|
|
Amy |
Redl |
|
|
|
Francis |
Rienzo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
General issues related to S.637 "Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Francis |
Rienzo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
General issues related to international intellectual property.
17. House(s) of Congress and Federal agencies Check if None
U.S. Trade Representative (USTR), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jacob |
Hartsfield |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOR
16. Specific lobbying issues
General issues related to patent reform.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Francis |
Rienzo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services, Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services, Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
General issues related to Buy American/American First; issues related to international drug pricing and reimbursement; and issues related to international market access.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), U.S. Trade Representative (USTR), State - Dept of (DOS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Francis |
Rienzo |
|
|
|
Jacob |
Hartsfield |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services, Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services, Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
General issues related to the Food and Drug Administration User Fee Reauthorization
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Francis |
Rienzo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services, Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services, Inc., so too Sanofi SA, as the parent corporation, will benefit.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
| Sanofi Pasteur |
|
|
||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |